I’d buy and hold these 3 FTSE 100 dividend growth shares for life

With a track record of dividend increases and world-leading positions in their respective markets, these FTSE 100 (INDEXFTSE:UKX) dividend stocks are portfolio essentials.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

In my opinion, one of the best dividend stocks in the FTSE 100 right now is pharmaceutical giant AstraZeneca (LSE: AZN).

A few years ago, it looked as if Astra was on the rocks. Patent expirations were weighing on earnings, and the company was struggling to find new treatments to fill its pipeline.

However, over the past three or four years, management has wholly reinvigorated the group. A relentless focus on finding new pharmaceutical products is starting to pay off, and the company is expected to return to growth in 2019 after several years of falling earnings. 

At the end of July, Astra reported its fourth successive quarter of rising revenues with sales increasing 19% to $5.7bn. Most of this growth is from new treatments. 

Management expects five of these treatments to reach blockbuster status in 2019, which means they will generate more than $1bn. CEO Pascal Soriot has described this as a “remarkable” performance for the company. 

Dividend growth

Astra is already a dividend champion, but this earnings growth suggests shareholders are in line for even bigger distributions going forward.

At present, the stock yields 3.2%, and the payout is covered 1.3 times by earnings per share. Cover is expected to hit 1.6 next year as earnings expand further, and I would expect Astra to make the most of this and increase its distribution to investors further. 

Another FTSE 100 dividend stock that I think could be a great addition to your portfolio today is Coca-Cola HBC AG (LSE: CCH).

Global partner

This is one of Coca-Cola’s major bottling partners, and the agreement with the drinks company gives the business a virtually guaranteed income stream. 

As a result, I think the dividend outlook for this firm is bright. While the stock might not offer the highest yield around (it currently yields 2.2%) the distribution is covered 2.3 times by earnings per share. It also has an impressive track record of dividend growth. 

Coca-Cola’s earnings per share have grown at a compound annual rate of 14% over the past six years as the business has branched out into new markets and improved operational efficiency. 

Earnings growth has allowed management to increase the dividend by an average of 10% every year, and I expect this trend to continue, given Coca-Cola’s market-leading position and track record of improving profit margins.

Market leader

The final FTSE 100 dividend stock that I would buy and hold forever is data giant Experian (LSE: EXPN).

Experian manages data that helps businesses and organisations to lend and prevent fraud.

In the world of data, bigger is always better. The more data you have, the better the service. And when it comes to data gathering, Experian has been a leader in the field since 2006, giving the firm a tremendous edge over its competitors.

As Experian has capitalised on its market position to grow, the dividend has grown at a compound annual rate of 5.1% over the past six years. The yield stands at 1.6% right now, but it’s covered 2.2 times by earnings per share, which gives plenty of room for growth going forward. 

The one downside is Experian’s premium valuation. The stock is trading at a forward price-to-earnings of 27 right now, but I think this is a price worth paying for such a world-leading business. 

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Rupert Hargreaves owns no share mentioned. The Motley Fool UK has recommended AstraZeneca and Experian. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

After it crashed 25%, should I buy this former stock market darling in my Stocks and Shares ISA?

Harvey Jones has a big hole in his Stocks and Shares ISA that he is keen to fill. Should he…

Read more »

happy senior couple using a laptop in their living room to look at their financial budgets
Investing Articles

How’s the dividend forecast looking for Legal & General shares in 2025 and beyond?

As a shareholder, I like to keep track of the potential dividend returns I could make from my Legal &…

Read more »

artificial intelligence investing algorithms
Investing Articles

Could buying this stock with a $7bn market cap be like investing in Nvidia in 2010?

Where might the next Nvidia-type stock be lurking in today's market? Our writer takes a look at one candidate with…

Read more »

Investing Articles

Is GSK a bargain now the share price is near 1,333p?

Biopharma company GSK looks like a decent stock to consider for the long term, so is today's lower share price…

Read more »

Snowing on Jubilee Gardens in London at dusk
Investing Articles

Could December be a great month to buy UK shares?

Christopher Ruane sees some possible reasons to look for shares to buy in December -- but he'll be using the…

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

Sticking to FTSE shares, I’d still aim for a £1,000 monthly passive income like this!

By investing in blue-chip FTSE shares with proven business models, our writer hopes he can build sizeable passive income streams…

Read more »

Growth Shares

BT shares? I think there are much better UK stocks for the long term

Over the long term, many UK stocks have performed much better than BT. Here’s a look at two companies that…

Read more »

British Pennies on a Pound Note
Investing Articles

After a 540% rise, could this penny share keep going?

This penny share has seen mixed fortunes in recent years. Our writer looks ahead to some potentially exciting developments in…

Read more »